• Users Online: 1365
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2019  |  Volume : 31  |  Issue : 4  |  Page : 958-964

The role of sclerostin in knee osteoarthritis and its relation to disease progression

1 Department of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2 Department of Rheumatology and Rehabilitation, Kafr Shokr Central Hospital, Qalyubiyah, Egypt

Correspondence Address:
MD Elham S Mohamed
Department of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, 11311
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ejim.ejim_108_19

Rights and Permissions

Background Osteoarthritis (OA) is a common joint disease especially in aging population and is characterized by progressive degeneration of articular cartilage, osteophyte formation, and subsequent joint space narrowing. Sclerostin, a protein product of the SOST gene, secreted mainly by osteocytes causes inhibition of Wnt/β-catenin signaling pathway and bone morphogenetic protein, therefore may affect bone formation and bone remodeling in OA. Aim The aim was to assess serum sclerostin level in patients with knee osteoarthritis (KOA) and its relation to disease severity. Patients and methods A total of 80 participants (50 KOA patients and 30 healthy controls) were recruited in the present study. Sclerostin level in plasma was assessed using an enzyme-linked immunosorbent assay. OA grading was performed using the Kellgren–Lawrence classification. Assessment of physical disability was done by Western Ontario and McMaster universities Arthritis index score and health assessment questionnaire score. Results Plasma sclerostin levels were significantly lower in patients with OA than in healthy controls (P<0.001). Moreover, serum sclerostin level demonstrated a significant inverse correlation with the physical disability score (r=−0.506, P<0.01), age (r=−0.295, P<0.01), disease duration (P<0.05), and radiographic severity of KOA (P<0.001). By univariate regression analysis, sclerostin was one of the strong negative predictors for severity of OA. Conclusion Sclerostin was significantly lower in OA plasma samples when compared with healthy controls. Serum sclerostin level was inversely associated with the physical disability and radiographic severity of KOA. Therefore, sclerostin may be used as a biochemical marker for reflecting disease severity in primary KOA.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded18    
    Comments [Add]    

Recommend this journal